Background. In the MAINTAIN Nephritis Trial, azathioprine (AZA) and mycophenolate mofetil (MMF) were compared as maintenance immunosuppressive treatment of proliferative lupus nephritis (LN) after a short-course of intravenous cyclophosphamide. Here, we compare the pathological findings on repeat kidney biopsies between the two groups. Methods. Per protocol, repeat renal biopsies were obtained in 30 patients (16 AZA and 14 MMF) at 2 years (66 months). Baseline and follow-up biopsies were graded according to the International Society of Nephrology/Renal Pathological Society (ISN/RPS) classification. The activity and chronicity indices (AI, CI) were calculated using two different semiquantitative scoring systems (Morel-Maroger and National Institutes of Health). Statistics were performed by non-parametric tests.
Introduction
Lupus nephritis (LN) occurs in up to 60% of patients suffering from systemic lupus erythematosus (SLE) [1] and significantly impacts their survival [2] . Renal relapses are common [3] and have been repeatedly identified as a poor prognostic factor for end-stage renal disease (ESRD) [4] , thereby justifying the need for long-term immunosuppression. Because of toxicity issues, most physicians have moved away from the National Institutes of Health (NIH) maintenance regime consisting of quarterly high-dose intravenous (IV) cyclophosphamide (CY) pulses given during 2 years after remission [5, 6] . Yet, the optimal maintenance therapy is still debated [7] . For years, we have been using azathioprine (AZA) [8] , but more recently, mycophenolate mofetil (MMF) has been proposed as an alternative.
Two recent randomized controlled trials have compared AZA and MMF for long-term immunosuppression of LN, the ASPREVA Lupus Management Study (ALMS) and the MAINTAIN Nephritis Trial. While superiority of MMF over AZA for the prevention of treatment failure was demonstrated in ALMS [9] , MAINTAIN failed to prove the superiority of MMF for the prevention of renal flares [10] . In this manuscript, we compare the effects of the two treatments on kidney histopathology by repeat biopsy analyses performed at 2 years in a subset of patients randomized in MAINTAIN.
Materials and methods

Clinical protocol
One hundred and five patients with biopsy-proven proliferative LN (WHO Classes III, IV, Vc or Vd) [11] were randomized in MAINTAIN by 27 European centres. The inclusion criteria, treatment regimes, primary end point (time to renal flare) and main clinical outcomes have been detailed elsewhere [10] . Briefly, all patients received three daily 750 mg IV methylprednisolone (MP) pulses (Days 1-3), followed by oral glucocorticoid (GC) therapy (starting dose: 0.5 mg equivalent prednisolone/kg/day). All patients received six fortnightly IVCY pulses of 500 mg (fixed dose) within a 10-week period and were then started, from Week 12 onwards, on AZA (target dose: 2 mg/kg/day; the 'GC/IVCY/AZA' group, further referred to as the AZA group) or MMF (target dose 2 g/day; the 'GC/ IVCY/MMF' group, further referred to as the MMF group), according to randomization performed at baseline and irrespectively of the magnitude of their renal response at 3 months. This investigator-initiated superiority trial did not receive external funding, was registered at www.ClinicalTrials.gov (NCT00204022) and approved by the ethics committees of all participating hospitals. Written informed consent was obtained and the trial was conducted according to the Good Clinical Practice guidelines of the European Medicines Agency.
Renal biopsies and pathological analyses
All patients had a baseline renal biopsy (inclusion criteria). A repeat biopsy was suggested to patients/investigators, per protocol, at 2 years (AE6 months) but was not compulsory to stay in the study and not intended to guide therapy. Thirty renal biopsy pairs (baseline/follow-up) were available for central review performed at the Pathology Department of the Cliniques Universitaires Saint-Luc (Université catholique de Louvain) by two pathologists (S.A. and J.P.C.; the latter being a senior nephropathologist with 35 years experience in LN). Both were unaware of treatment allocation and clinical outcome of all patients and of the biopsy order in 19 of the 30 biopsy pairs. Permanent date labelling was present on the other 11 renal biopsy slides, thereby preventing blinding of the biopsy order.
Baseline and follow-up biopsies were classified according to the International Society of Nephrology/Renal Pathological Society 2003 classification criteria [12] . Histological slides (haematoxylin/eosin, periodic acid schiff, Jone's silver staining) and immunofluorescence (IF) slides (IgG, IgA, IgM, C3, C1q and fibrin) were available on all biopsy pairs but for one of which, IF slides were missing. Activity and chronicity indices (AI, CI) were computed according to two semiquantitative scoring systems proposed by Morel-Maroger [13] and by Austin (NIH score, 14) . Briefly, in the Morel-Maroger scoring system, the AI (maximum score: 42) is the sum of four scores for hyperactive lesions (Gross haematoxylin bodies, circumferential crescents, glomerular necrosis and necrotizing angeitis) and six scores for active lesions (endocapillary proliferation, partial crescents, wire loops, hyaline thrombi, nuclear debris and acute tubulointerstitial lesions). The active and hyperactive lesions are graded on a scale of 0-3 (absent: 0; mild: 1; moderate: 2 and severe: 3). Hyperactive lesions are weighted by a factor 2, as they are considered to be a more significant marker of activity. The Morel-Maroger CI (maximum score: 6) is the sum of two scores (graded 0-3: absent, mild, moderate and severe) for chronic lesions (glomerular and interstitial fibrosis). In the NIH scoring system, the AI (maximum score: 24) is the sum of six scores: glomerular cell proliferation (0-3), leucocyte exsudation (0-3), karyorrhexis and fibrinoid necrosis (0-3; weighted by a factor of two), cellular crescents (0-3; weighted by a factor of two), hyaline deposits (0-3) and interstitial inflammation (0-3), as described [14] . The NIH CI (maximum score: 12) is the sum of four scores: glomerular sclerosis (0-3), fibrous crescents (0-3), tubular atrophy (0-3) and interstitial fibrosis (0-3).
Statistical analyses
Wilcoxon signed ranks test or Mann-Whitney tests were used as indicated for intra-group and inter-group comparisons for continuous variables, respectively. Chi-square and Fisher's exact tests were used for comparisons between discontinuous variables. All analyses were by intent-to-treat.
Results
Clinical characteristics
Per protocol, repeat kidney biopsies were obtained in 30 patients (from 13 centres) randomized in the MAINTAIN Nephritis Trial. As indicated in Table 1 , the clinical characteristics of these 30 re-biopsied patients only marginally differs from the entire MAINTAIN cohort. Sixteen of them had been assigned AZA and 14 MMF. Table 2 compares their serum creatinine, serum albumin and 24-h proteinuria values as well as their ECLAM (European Consensus Lupus Activity Measurement) and SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) scores at baseline and at the time of repeat biopsy. Renal parameters and clinical activity scores significantly and similarly improved in both groups. A mean (SD) of 16 [11] and 15 [8] glomeruli were available for baseline and follow-up pathological analyses, respectively. Less than 10 glomeruli were available in 10 of the 30 baseline biopsies (between 3 and 9 glomeruli) and in 7 of the 30 follow-up biopsies (between 4 and 7 glomeruli).
ISN/RPS class shifts
Fourteen baseline/repeat biopsy pairs in each treatment group could be classified according to the ISN/RPS classification. Two baseline/repeat biopsy pairs could not be classified because IF data were missing. As illustrated in Figure 1 , most patients had Class IV (AEV) LN at baseline (10/14 in the AZA group and 11/14 in the MMF group). At follow-up, only five and seven biopsies were still classified as Class IV (AEV) in AZA and MMF patients, respectively. Conversely, in both groups, more patients had normal or Classes I/II/V LN at follow-up compared to baseline.
Activity/chronicity indices
As indicated in Table 3 , the activity index, using both scoring systems (Morel-Maroger and NIH), significantly dropped at follow-up in both groups, without differences between groups. Correlation between the two AI was good (r 2 ¼ 0.71; P < 0.0001). No necrotizing angeitis lesions and only few other hyperactive lesions according to MorelMaroger (Gross haematoxylin bodies, circumferential crescents and glomerular necrosis) were observed at baseline (Figure 2A and B), thereby preventing statistical analyses. Evolution of active lesions according to Morel-Maroger (endocapillary proliferation, partial crescents, wire loops, hyaline thrombi, nuclear debris and acute tubulointerstitial lesions) is depicted in Figure 2C and D. Most of them significantly improved in both treatment groups. The CI using both scores, slightly, but significantly, worsened over time in both groups, again without difference between groups (Table 4) . Correlation between the two CI was good (r 2 ¼ 0.75; P < 0.0001).
Correlation with renal flares
Of the 30 patients who underwent a second renal biopsy, only 4 (3 MMF and 1 AZA) had suffered from a renal flare (the primary outcome of the trial) before the per protocol control biopsy, namely at Months 12, 14, 20 and 30. Their immunosuppressive treatment had therefore been modified before the per protocol repeat biopsy; one AZA patient had been switched to MMF, one MMF patient was given pulse IV MP therapy and high-dose oral GCs, one MMF patient CY and one MMF patient high-dose oral GCs. It is likely that the histological data from these four renal biopsies, obtained after treatment shift, were influenced by these treatment changes, but we included them since we had decided to perform an intention-to-treat analysis for all outcome measures of the trial. By the time of the second biopsy, the 26 remaining patients were still on their allocated immunosuppressant.
However, three of these patients (two AZA and one MMF) suffered from a renal flare after repeat biopsy (at Months 21, 32 and 48). Interestingly, the AI was low in two of them.
Correlation between AI at repeat biopsy and long-term renal outcome
We wondered whether patients with pathological evidence of persistently active disease at repeat biopsy (defined has having a NIH AI at repeat biopsy superior to the mean NIH AI of the entire group, i.e. >4) had a poorer long-term renal outcome. Interestingly, the eight patients with an NIH AI !4 at repeat biopsy had a similar serum creatinine (mean: 0.78 mg/dL) at last follow-up (mean: 49 months) compared to the 22 patients who had an NIH AI 4 at repeat biopsy (mean serum creatinine: 0.81 mg/dL; mean follow-up: 54 months).
Kidney biopsy-related adverse events
Two of the 60 renal biopsies were complicated by pain and ultrasound/computerized tomography confirmed renal haematoma: one at baseline and one, in another patient, at repeat biopsy. Both episodes were self-limited and did not require any other therapy other than short-term analgesics.
Discussion
Per protocol repeat renal biopsies were obtained in a representative subset of patients randomized in the MAINTAIN Nephritis Trial, an European-based investigator-initiated controlled study comparing GC and IVCY followed by AZA (AZA group) versus GC and IVCY followed by MMF (MMF group) as treatment of proliferative LN. Centralized blinded pathological analyses, including ISN/RPS classification and calculations of AI/CI, failed to reveal an advantage of MMF over AZA, a result well in line with the absence of difference in clinical outcome reported elsewhere [10] . Taken together, the results of MAINTAIN differ from those recently reported in abstract form for the ALMS trial [9] , which demonstrated superiority of MMF over AZA for the prevention of treatment failure (the primary end point), a composite index made of five items (death, ESRD, initiation of rescue therapy for LN, sustained doubling of serum creatinine (DSC) and proteinuric/nephritic renal flare). Of note, the primary end point of MAINTAIN was a single item (renal flare), a more stringent definition of renal flare was applied, follow-up was longer and repeat kidney biopsies were obtained and evaluated. On the other hand, ALMS was a larger trial, a blinded study and included much more non-Caucasians. This being said, while both trials will inevitably be compared, their design differs so much that head-to-head comparison should be avoided. ALMS patients were randomized in the maintenance phase only if they had experienced a sufficient response to the induction therapy, thereby leading to exclusion of half of the patients at Week 24. Moreover, induction therapy was either with MMF or with IVCY, a design that might have skewed the results in favour of MMF at least for patients given (and by definition responding to) this drug in the first part of the trial. In MAINTAIN, randomization was performed at baseline, all patients received the same initial immunosuppression regime and were switched to AZA or MMF at Week 12, irrespectively of the magnitude of their renal response at 3 months. MAINTAIN is therefore not a comparison of AZA versus MMF but of a combination of GC, IVCY and AZA versus a combination of GC, IVCY and MMF, with a homogeneous induction phase. Few repeat renal biopsy studies have been reported in LN patients [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , and in most of them, the second biopsy was obtained at different time intervals for clinical reasons, such as a worsening of renal function or other signs of renal relapses rather than per protocol, at a fixed timeline, thereby introducing a potential bias. To the best of our knowledge, only two repeat renal biopsy studies (other than the one reported here) were performed in patients randomized in a controlled trial aimed at comparing different treatments [15, 16] . Thus, in a seminar paper published 25 years ago, Balow et al. [15] demonstrated that the CI for patients treated with high-dose GC increased linearly with the interval between biopsies, whereas it did not in the group receiving additional cytotoxic drugs, a pivotal observation that contributed very much to the use of combined immunosuppressive therapy in LN. In another recent randomized trial, in which repeat renal biopsies were obtained per protocol after 2 years and were not used to guide therapy, Grootscholten et al. [16] showed that treatment with IVCY delayed the progression of chronic lesions more efficiently than AZA (combined to IV pulse MP) in patients with proliferative LN. Intriguingly, after a medium-term follow-up, they could not demonstrate the prognostic value, in terms of long-term renal outcome, of any of the histopathological variables evaluated at baseline or at repeat biopsy. This observation contrasts with some previous studies. Hill et al. [17] , using a composite biopsy index assessing glomerular activity, tubulointerstitial activity, chronic lesions and IF indices, could demonstrate the predictive power for long-term DSC of a repeat renal biopsy (but not of the corresponding baseline biopsy) performed at the end of a 6-month IVCY induction regime. Moreover, in the same group of patients, they could demonstrate that scarring was partially reversible in a significant proportion of patients and that this reversal positively correlated with a good renal outcome [18] . In another study performed in LN patients, Esdaile et al. [19] demonstrated that the persistence/worsening of sub-endothelial and sub-epithelial electron-dense deposits on control biopsies was associated with a poor renal outcome. On the whole, whether renal biopsy findings help predict longterm renal outcome in LN patients remains debatable. The trend towards lower DSC/ESRD rates at 10 years in recent randomized trials [10] will probably make this issue even more difficult to address in the future, except with very long follow-up periods and the use of more sensitive techniques aimed at detecting early fibrotic changes on control renal biopsy samples, such as immunohistochemistry stainings for fibronectin, collagens, a-smooth muscle actin or transforming growth factor-b [20] .
Taken together, the pathological data presented here, although obtained in a subset of patients randomized in MAINTAIN, fail to demonstrate a difference between MMF and AZA maintenance therapy for proliferative LN. Active lesions include endocapillary proliferation, partial crescents, wire loops, hyaline thrombi, nuclear debris and acute tubulointerstitial lesions. First: baseline renal biopsy; second: follow-up renal biopsy. P-values were calculated by Wilcoxon signed ranks test. *P < 0.05; **P < 0.01; ***P 0.005.
